Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cabaletta Bio ( (CABA) ) has issued an update.
On May 14, 2026, Cabaletta Bio planned to present new clinical and translational data from four refractory pemphigus vulgaris patients treated with the lowest dose of rese-cel without preconditioning in its RESET-PV trial, with follow-up ranging from 24 to 36 weeks as of the April 2, 2026 data cut-off. After discontinuing all immunomodulators, the company reported clear biologic and clinical activity, including compelling responses in two patients, sustained steroid- and immunomodulator-free status in three patients, robust peripheral B cell elimination in three patients, and a favorable safety profile marked by only one case of mild cytokine release syndrome and no neurotoxicity, supporting dose escalation in RESET-PV and parallel progress in the RESET-SLE lupus trial, where the initial no-preconditioning dose cohort has been fully enrolled.
The most recent analyst rating on (CABA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Neutral.
The score is held back mainly by weak financial performance (no revenue, widening losses, and heavy cash burn with shrinking equity), partially offset by constructive technical momentum and positive corporate updates that add pipeline and funding runway support. Valuation provides limited support due to a negative P/E and no dividend.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio is a biotechnology company focused on developing cell therapies for autoimmune diseases, including pemphigus vulgaris and systemic lupus erythematosus. Its lead candidate, rese-cel, is being evaluated across multiple RESET clinical trials targeting refractory patients who have limited treatment options in these indications.
Average Trading Volume: 2,296,370
Technical Sentiment Signal: Buy
Current Market Cap: $327.3M
For an in-depth examination of CABA stock, go to TipRanks’ Overview page.